We are live on ! Find out more
PCVX icon

Vaxcyte
PCVX

88 hedge funds and large institutions have $1.2B invested in Vaxcyte in 2022 Q1 according to their latest regulatory filings, with 12 funds opening new positions, 36 increasing their positions, 22 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more funds holding in top 10

Funds holding in top 10: 4 → 8 (+4)

64% more repeat investments, than reductions

Existing positions increased: 36 | Existing positions reduced: 22

13% more capital invested

Capital invested by funds: $1.06B → $1.2B (+$142M)

3.82% more ownership

Funds ownership: 84.71% → 88.54% (+3.8%)

1% more funds holding

Funds holding: 87 → 88 (+1)

9% more first-time investments, than exits

New positions opened: 12 | Existing positions closed: 11

Holders
88
Holders Change
+1
Holders Change %
+1.15%
% of All Funds
1.39%
Holding in Top 10
8
Holding in Top 10 Change
+4
Holding in Top 10 Change %
+100%
% of All Funds
0.13%
New
12
Increased
36
Reduced
22
Closed
11
Calls
$751K
Puts
–
Net Calls
+$751K
Net Calls Change
+$249K

Top Buyers

Rank Fund Capital Flow
1
EC
EcoR1 Capital
California
+$28.1M
2
Citadel Advisors
Citadel Advisors
Florida
+$13.9M
3
Fidelity Investments
Fidelity Investments
Massachusetts
+$11M
4
Vanguard Group
Vanguard Group
Pennsylvania
+$10.8M
5
O
OrbiMed
New York
+$9.11M

Top Sellers

Rank Fund Capital Flow
1
FM
Frazier Management
Washington
-$54.9M
2
TGA
TPG GP A
Texas
-$3.33M
3
WP
Woodline Partners
California
-$2.32M
4
OM
Opaleye Management
Massachusetts
-$2.29M
5
Bank of America
Bank of America
North Carolina
-$799K
Name Holding Trade Value Shares
Change 		Change in
Stake
OM
26
Opaleye Management
Massachusetts
$5.1M -$2.29M -104,800 -33%
State of Wisconsin Investment Board
27
State of Wisconsin Investment Board
Wisconsin
$5M – – –
Bank of New York Mellon
28
Bank of New York Mellon
New York
$3.68M +$151K +6,891 +5%
N
29
Nuveen
North Carolina
$3.48M -$33.2K -1,518 -1%
DCM
30
Driehaus Capital Management
Illinois
$2.17M +$1.97M +90,000 New
Victory Capital Management
31
Victory Capital Management
Texas
$2.15M +$1.94M +89,010 New
Morgan Stanley
32
Morgan Stanley
New York
$2.15M +$679K +31,088 +54%
Walleye Capital
33
Walleye Capital
New York
$1.68M +$1.52M +69,452 New
UBS Group
34
UBS Group
Switzerland
$1.46M +$331K +15,152 +33%
Rafferty Asset Management
35
Rafferty Asset Management
New York
$1.4M +$258K +11,792 +25%
Alyeska Investment Group
36
Alyeska Investment Group
Illinois
$1.26M +$1.14M +52,100 New
RhumbLine Advisers
37
RhumbLine Advisers
Massachusetts
$1.23M +$84.2K +3,852 +8%
Swiss National Bank
38
Swiss National Bank
Switzerland
$1.21M +$89.6K +4,100 +9%
Barclays
39
Barclays
United Kingdom
$1.2M +$1.09M +49,800 New
AllianceBernstein
40
AllianceBernstein
Tennessee
$1.06M +$151K +6,900 +19%
Renaissance Technologies
41
Renaissance Technologies
New York
$985K +$607K +27,800 +214%
Bank of America
42
Bank of America
North Carolina
$929K -$799K -36,589 -49%
BBHC
43
Brown Brothers Harriman & Co
New York
$918K – – –
California State Teachers Retirement System (CalSTRS)
44
California State Teachers Retirement System (CalSTRS)
California
$877K -$68.8K -3,151 -8%
Ensign Peak Advisors
45
Ensign Peak Advisors
Utah
$867K +$753K +34,480 +2,428%
New York State Common Retirement Fund
46
New York State Common Retirement Fund
New York
$740K +$44.3K +2,027 +7%
BFM
47
Boothbay Fund Management
New York
$733K +$15.1K +689 +2%
Temasek Holdings
48
Temasek Holdings
Singapore
$659K – – –
Invesco
49
Invesco
Georgia
$656K +$278K +12,719 +88%
JP Morgan Chase
50
JP Morgan Chase
New York
$647K +$140K +6,390 +31%
1
2
3 4

PCVX Hedge Fund Activity: Q1 2022 in Review

88 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Vaxcyte (PCVX) for Q1 2022, worth a combined $1.2B — up 13% from $1.06B a quarter earlier.

Buyers outnumbered sellers: 12 funds opened new PCVX positions and 11 closed out — a net gain of 1 holder — while 36 added to existing stakes and 22 trimmed.

The largest buyer was EcoR1 Capital, adding an estimated $28.1M. The largest seller was Frazier Management, exiting entirely with an estimated $54.9M sold.

  • 88 institutional investors held Vaxcyte (PCVX) as of Q1 2022, up from 87 in Q4 2021.
  • Funds reported $1.2B of Vaxcyte stock for Q1 2022, up 13% quarter-over-quarter.
  • 12 funds opened new Vaxcyte positions in Q1 2022 and 11 closed out, a net change of +1 holder.
  • The largest Vaxcyte buyer in Q1 2022 was EcoR1 Capital, an estimated $28.1M added.
  • The largest Vaxcyte seller in Q1 2022 was Frazier Management, an estimated $54.9M sold.

Based on aggregated 13F filings for Q1 2022.